APA (7th ed.) Citation

Vallis, K., Reilley, R., Scollard, D., Petronis, J., Caldwell, C., Hendler, A., . . . Oza, A. (2005). A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer.

Chicago Style (17th ed.) Citation

Vallis, K., R. Reilley, D. Scollard, J. Petronis, C. Caldwell, A. Hendler, G. Lockwood, and A. Oza. A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Toxicity and Dosimetry of 111-indium-labeled Human Epidermal Growth Factor in Patients with Metastatic Breast Cancer. 2005.

MLA (9th ed.) Citation

Vallis, K., et al. A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Toxicity and Dosimetry of 111-indium-labeled Human Epidermal Growth Factor in Patients with Metastatic Breast Cancer. 2005.